---
title: 'Vice President, Medical Affairs-Ophthalmology at Annexon Biosciences'
canonical: 'https://feeny.ai/job/vice-president-medical-affairs-ophthalmology-annexon-biosciences-san-francisco-4k8s7zf170d6'
type: 'job'
last_seen: '2026-09-13'
---

# Vice President, Medical Affairs-Ophthalmology at Annexon Biosciences

- **Company:** Annexon Biosciences
- **Location:** San Francisco, CA
- **Posted:** 2026-04-06
- **Last confirmed live:** 2026-09-13
- **Apply:** https://job-boards.greenhouse.io/annexonbioscience/jobs/4681901005

## Job description

Company:

At Annexon Biosciences we are a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Our novel scientific approach targets upstream C1q to block the classical complement inflammatory cascade before it starts, and its therapeutic candidates are designed to provide meaningful benefits across multiple autoimmune, neurodegenerative and ophthalmic diseases. With proof-of concept data in Guillain-Barré syndrome, Huntington’s disease and geographic atrophy, we are rigorously advancing our mid-to late-stage clinical trials to bring new potential treatments to patients as quickly as possible. At Annexon, you’ll be part of a team committed to making an impact together.

For more information on Annexon and our pipeline, check out our site [Annexon Biosciences](https://annexonbio.com/) & [Annexon Pipeline](https://annexonbio.com/pipeline/). We trade on Nasdaq under the ticker symbol ANNX and are headquartered in Brisbane, CA.

We're seeking exceptional talent from all backgrounds to fuel our growth. At Annexon, we're building a diverse, equitable, and inclusive workplace. We value unique perspectives and unconventional paths. If you're the best candidate for the job, even if you don't perfectly fit the traditional mold, we encourage you to apply. Learn more about our commitment to diversity, equity, inclusion, and our company [culture](https://annexonbio.com/our-culture/)!

Position:

The Vice President, Ophthalmology Medical Affairs will be responsible for representing Annexon Biosciences with a network of external thought leaders and driving Global Medical Affairs activities in complement-mediated diseases in Ophthalmology.

Responsibilities include:

- As a key member of the ophthalmology core team, provide deep medical and scientific expertise on medical affairs, launch, and lifecycle strategies.
- Lead the full spectrum of the Medical Affairs functions that are responsible for the development and implementation of the Global medical strategy across the following areas:
- Medical Affairs Operations – focused on communication, medical education, advisory management, and patient advocacy.
- Medical Science Liaison – directed at work with practicing physicians, key opinion leaders, academic physicians, and other health care providers who deliver care to the targeted patient populations for which Annexon products are directed.
- Partner closely with the organization in the establishment of our market access strategies that enables plans for pricing, reimbursement, and access.
- Establish appropriate strategic partnerships with internal leaders in clinical development, regulatory affairs, safety, operations, research, and commercial.
- Extend and grow the established professional relationships with the external expert community to maintain cutting edge knowledge about the disease areas in which we operate, standards of practice within those areas, and the evolving unmet medical need.
- Enrich the relationship we have with patients and patient advocacy groups for both clinical trials and commercial planning, and understanding of needs that we can better serve.
- Represent Annexon as an organization, and present data at advisory boards, , clinical investigator meetings, congresses, symposia, and other scientific forums.
- Remain at the forefront of the relevant science and competitive landscape.
- Collaborate with legal, compliance, and regulatory authorities to ensure proper and ethical interactions between medical affairs personnel and external stakeholders.

Education, Experience, and Skills:

Required:

- Advanced degree (MD, PhD, or PharmD) preferred.
- A minimum of 15 years Medical Affairs experience within the biopharma industry.
- Prior experience in product launch or launches in ophthalmology.
- Skilled at engagement and scientific exchange with the external medical community and has an established network of medical and clinical contacts.
- Proven ability to lead, manage, and motivate others in a multi-functional matrix environment.
- Experience in global/regional/local medical practice and healthcare ecosystems.
- Knowledge of Good Clinical Practices (GCP), region regulations and guidelines, and applicable international regulatory requirements.
- Finance/budgeting and resource management experience.
- Skilled at effectively presenting ideas and documenting complex medical/clinical concepts in both written and oral communication.
- History of solving problems while exhibiting superior judgment and a balanced, realistic understanding of issues.
- Ensures representation of the patient perspective/ “voice of patient”.

Salary Range: $354,200 - $377,000

Location: Annexon Biosciences is located in Brisbane, California and preference is given to candidates in the San Francisco Bay Area.

Benefits:

- A stimulating and rewarding workplace includes flexible work schedules, remote opportunities and the ability to achieve a work-life balance.
- Shuttle service from BART, CalTrain and the Ferry.
- Annexon offers a competitive base salary and equity participation, employee stock purchase plan, as well as a comprehensive health benefit package that includes medical, dental, vision, 401(k), flexible spending plans, and other benefits.

Annexon Biosciences is an Equal Opportunity Employer, and we prohibit discrimination or harassment of any kind.  We are committed to fostering an environment where ALL people are welcome and supported. We cultivate a culture of inclusion for all employees that respects their individual strengths, views, and experiences. We believe that our differences enable us to be a better team – one that makes better decisions, drives innovation, and delivers better business results. Creativity and innovation flourish in an environment of openness, inclusion, and mutual respect.

## About Annexon Biosciences

## Company Overview
- **One-liner**: Annexon Biosciences is a clinical-stage biopharmaceutical company pioneering the development of C1q inhibitors to stop classical complement-mediated neuroinflammation in autoimmune, neurodegenerative, and ophthalmic diseases.
- **Entity Type**: Public (Nasdaq: ANNX)
- **Headquarters**: Brisbane, California, USA
- **Founded**: 2007
- **Founders**: Dr. Ben Barres (co‑founder, deceased) and Dr. Arnon Rosenthal

## Core Business
- **Industry**: Biopharmaceuticals – complement‑targeted therapeutics
- **Target Customers**: Patients and healthcare providers treating classical complement‑mediated diseases (body, brain, eye); B2B partnerships with clinical sites and payers
- **Mission**: “Deliver game‑changing therapies to patients so that they can live their best lives” [annexonbio.com](https://annexonbio.com/about/)

## Products & Services
Annexon’s pipeline is based on inhibiting C1q, the initiating molecule of the classical complement pathway. Key investigational candidates:
- **ANX005**: A monoclonal antibody targeting C1q for intravenous administration. Lead indication is Guillain‑Barré Syndrome (GBS); completed enrollment in a Phase 3 pivotal program – the first such program in GBS in 40 years – and has Orphan Drug Designation from the EMA [annexonbio.com](https://annexonbio.com/about/)
- **ANX007**: An intravitreal antibody fragment targeting C1q for ophthalmic use. Demonstrated statistically significant, dose‑dependent preservation of visual function in a Phase 2 trial in geographic atrophy (GA) [annexonbio.com](https://annexonbio.com/about/)
- **ANX009**: A subcutaneous formulation of ANX005 designed for chronic autoimmune and neurodegenerative indications. Achieved full target engagement in the blood compartment in a Phase 1 healthy volunteer study [annexonbio.com](https://annexonbio.com/about/)
- **ANX1502**: An oral small‑molecule inhibitor of the classical complement pathway. Achieved target pharmacokinetics in a Phase 1 healthy volunteer study [annexonbio.com](https://annexonbio.com/about/)

## Market Standing
- **Valuation / Market Cap**: Not publicly available from provided sources (public company, market cap fluctuates)
- **Key Metric**: Publicly traded (Nasdaq: ANNX); recent major milestones include Phase 3 completion for ANX005 in GBS and Phase 2 data for ANX007 in GA
- **Notable Investors / Partners**: Leaders on board and scientific advisory board include Stephen Hauser (MD, UCSF), Beth Stevens (PhD, Harvard), David Holtzman (MD, Washington University), and others. The co‑founder Dr. Ben Barres was a highly respected neuroscientist [annexonbio.com](https://annexonbio.com/about/)
- **Growth Signals**: Initial public offering in 2020 funded pipeline expansion; active recruiting for senior clinical and medical affairs roles (Senior Director, Clinical Development; VP, Drug Safety; etc.) suggests advancement toward late‑stage trials and potential commercialization [greenhouse.io](https://job-boards.greenhouse.io/annexonbioscience)

## Competitive Advantages
- **First‑in‑class C1q inhibitor focus**: By targeting the top of the classical complement pathway, Annexon aims to block all downstream damaging components rather than a single downstream effector.
- **Broad pipeline across three therapeutic areas** (autoimmunity, neurodegeneration, ophthalmology) targeting nearly 10 million patients worldwide.
- **Biomarker‑driven, disciplined strategy** to improve probability of technical success and deliver precision medicine [ir.annexonbio.com](https://ir.annexonbio.com/corporate-profile)
- **Strong scientific foundation** built on decades of research by co‑founder Dr. Ben Barres on C1q’s role in synapse loss.

## Strategic Focus
- Completing the first Phase 3 program for GBS in 40 years (ANX005) and preparing for regulatory submissions.
- Advancing ANX007 through pivotal trials for geographic atrophy and exploring glaucoma.
- Developing subcutaneous and oral formulations (ANX009, ANX1502) to expand into chronic, less invasive treatment paradigms.
- Employing precision‑medicine biomarkers to identify patients most likely to benefit from classical complement inhibition.

## Why Work Here
- **Culture**: Described as “show up with your heart and mind … team‑based, follow the science.” Core values include warrior spirit, all‑for‑one teamwork, sound judgment, passion, and a thrive mentality [annexonbio.com/careers](https://annexonbio.com/careers/)
- **Work Environment**: Flexible work schedules, remote opportunities, and a Brisbane, CA office with shuttle service from BART, CalTrain, and the Ferry [annexonbio.com/careers](https://annexonbio.com/careers/)
- **Benefits**: Competitive base salary, equity participation, employee stock purchase plan (ESPP), medical/dental/vision insurance, 401(k), flexible spending plans, and a focus on work‑life balance [annexonbio.com/careers](https://annexonbio.com/careers/)
- **Team**: About 4 open positions as of mid‑2026 (Senior Director Clinical Development, VP Drug Safety, etc.) – a small, driven team where contributions are visible and valued [greenhouse.io](https://job-boards.greenhouse.io/annexonbioscience)

## Sources
1. [annexonbio.com – Home](https://annexonbio.com/)
2. [ir.annexonbio.com – Corporate Profile](https://ir.annexonbio.com/corporate-profile)
3. [annexonbio.com – About (Leadership, History, Mission)](https://annexonbio.com/about/)
4. [annexonbio.com – Careers (Culture, Benefits, Values)](https://annexonbio.com/careers/)
5. [greenhouse.io – Jobs at Annexon Biosciences](https://job-boards.greenhouse.io/annexonbioscience)

## Other roles at Annexon Biosciences

- [Senior Director, Global Scientific Communications](https://feeny.ai/job/senior-director-global-scientific-communications-annexon-biosciences-san-ygq0cdyxzd03) — San Francisco, CA
- [Executive Director & Head Clinical Data Management](https://feeny.ai/job/executive-director-head-clinical-data-management-annexon-biosciences-san-srwq0ehec0wz) — San Francisco, CA
- [Field Medical Director (MSL) – Ophthalmology (Southeast Region)](https://feeny.ai/job/field-medical-director-msl-ophthalmology-southeast-region-annexon-biosciences-f7eyw4qqefam) — San Francisco, CA
- [Senior Director, Regulatory Affairs](https://feeny.ai/job/senior-director-regulatory-affairs-annexon-biosciences-san-francisco-b2av8f6dqd9f) — San Francisco, CA
- [Senior Director, Medical Writing](https://feeny.ai/job/senior-director-medical-writing-annexon-biosciences-san-francisco-kxv9t4ghnxry) — San Francisco, CA
- [Associate Director, Clinical Trial Management](https://feeny.ai/job/associate-director-clinical-trial-management-annexon-biosciences-san-francisco-h3rh38k6a3ek) — San Francisco, CA
- [Senior Director, Drug Safety and Pharmacovigilance](https://feeny.ai/job/senior-director-drug-safety-and-pharmacovigilance-annexon-biosciences-san-w7jhxhsm0t09) — San Francisco, CA
- [Vice President, Medical Affairs-Neuroscience](https://feeny.ai/job/vice-president-medical-affairs-neuroscience-annexon-biosciences-san-francisco-vec8c090165d) — San Francisco, CA
- [Vice President, Clinical Development-Ophthalmology](https://feeny.ai/job/vice-president-clinical-development-ophthalmology-annexon-biosciences-san-8j8gnj3vpggn) — San Francisco, CA